Dilution of Share Value Through the Exercise of Stock Acquisition Rights
First written in FY2018. 11 of 12 entries say "Mitigated", first in FY2019. Latest entry: FY2026.
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
52 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Unexercised balance at beginning of period 413,100 521 Exercise △355,000 521 Unexercised balance at period-end 58,100 525 Exercisable balance at period-end 58,100 525」
The exercise of share acquisition rights covered 355,000 shares, and the unexercised balance at period-end fell sharply from 413,100 shares to 58,100 shares. Potential dilution has declined. - FY2026-H1MitigatedAnnual report
「Between the end of the interim accounting period and the end of the month preceding the filing date (31 January 2026), the total number of shares issued increased by 10,100 shares, capital increased by ¥3 million, and capital surplus increased by ¥3 million as a result of the issuance of new shares through the exercise of share acquisition rights.」
The issuance of shares through the exercise of share acquisition rights progressed, increasing the total number of shares issued by 10,100. The outstanding potential dilution factor continued to decline. - FY2025MitigatedAnnual report
「Unexercised balance at beginning of period 471,500 521 Exercise △58,400 520 Unexercised balance at period-end 413,100 521 Exercisable balance at period-end 413,100 521」
The stock options' unexercised balance at period-end decreased from 471,500 shares in the previous period to 413,100 shares, reducing potential dilution. - FY2024MitigatedAnnual report
「Unexercised balance at period-end 550,000 521 Exercisable balance at period-end 471,500 521」
The stock options' unexercised balance at period-end decreased from 550,000 shares in the previous period to 471,500 shares, reducing potential dilution. - FY2023MitigatedAnnual report
「Unexercised balance at period-end 550,000 Exercisable balance at period-end 550,000」
The stock options' unexercised balance at period-end decreased from 654,000 shares in the previous period to 550,000 shares, reducing potential dilution. - FY2022MitigatedAnnual report
「Unexercised balance at period-end 654,000 Exercisable balance at period-end 654,000」
The unexercised balance at period-end decreased from 780,100 shares in the previous period to 654,000 shares, reducing potential dilution. - FY2021MitigatedAnnual report
「Unexercised balance at period-end 780,100 Exercisable balance at period-end 562,300」
The stock options' unexercised balance at period-end decreased from 873,800 shares in the previous period to 780,100 shares, reducing potential dilution. - FY2020MitigatedAnnual report
「Unexercised balance at period-end 873,800 Weighted-average exercise price ¥522」
The stock options' unexercised balance at period-end decreased from 1,127,500 shares in the previous period to 873,800 shares. The potential dilution of equity value from the exercise of share acquisition rights has declined. - FY2019MitigatedAnnual report
「As of 31 August 2019, the number of potential shares underlying unexercised stock acquisition rights totaled 1,113,700 shares, equivalent to 8.9% of the total number of issued shares of 12,501,800. If exercised in the future, they may dilute the value of the Company's shares.」
The number of outstanding potential shares and the ratio to total shares issued decreased from the previously stated 1,237,500 shares and 10.0% to 1,113,700 shares and 8.9%, respectively. - FY2018First statedAnnual report
「As of 31 August 2018, the number of potential shares underlying unexercised stock acquisition rights totaled 1,237,500 shares, equivalent to 10.0% of the total number of issued shares of 12,392,000. If exercised in the future, they may dilute the value of the Company's shares.」
The disclosure shows the number of potential shares underlying unexercised stock acquisition rights and their ratio to the total number of issued shares, and describes the risk of dilution upon future exercise.